Who Can Benefit from Nicotinamide Adenine Dinucleotide (NAD+) Supplementation?

Nicotinamide adenine dinucleotide (NAD+) is a vital coenzyme involved in cellular energy metabolism, DNA repair, and regulation of circadian rhythms. While NAD+ levels naturally decline with age and in certain pathological conditions, supplementation—often via precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN)—is being investigated for potential supportive roles in specific populations.

Current evidence suggests that individuals with age-related metabolic decline—such as reduced mitochondrial function, insulin resistance, or diminished exercise capacity—may benefit from NAD+ precursor supplementation, particularly in the context of clinical trials. Older adults experiencing fatigue, cognitive slowing, or muscle weakness may represent a target demographic, though robust, large-scale human data remain limited.

Emerging research also explores NAD+ modulation in neurodegenerative conditions—including Alzheimer’s and Parkinson’s disease—as well as in patients recovering from chemotherapy-induced peripheral neuropathy or radiation injury, where DNA repair mechanisms are critically engaged. Additionally, preliminary studies indicate possible relevance in chronic inflammatory states and metabolic disorders like nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes, given NAD+’s role in sirtuin activation and redox homeostasis.

It is important to emphasize that NAD+ supplementation is not FDA-approved for any disease indication. Safety profiles appear favorable in short-term trials, but long-term effects, optimal dosing, and interactions with medications—including antihypertensives and anticoagulants—require further investigation. Individuals considering NAD+ precursors should consult a qualified healthcare provider, especially those with active malignancy, pregnancy, or severe hepatic or renal impairment.